Compare HBB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | ADCT |
|---|---|---|
| Founded | 1904 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9M | 483.1M |
| IPO Year | 2017 | 2020 |
| Metric | HBB | ADCT |
|---|---|---|
| Price | $16.59 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 30.8K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 24.53 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $607,430,000.00 | $75,209,000.00 |
| Revenue This Year | N/A | $10.36 |
| Revenue Next Year | N/A | $3.87 |
| P/E Ratio | $7.06 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $12.72 | $1.05 |
| 52 Week High | $21.20 | $4.80 |
| Indicator | HBB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 42.49 |
| Support Level | $15.62 | $3.35 |
| Resistance Level | $17.23 | $4.05 |
| Average True Range (ATR) | 0.73 | 0.27 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 80.90 | 22.77 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).